Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
Phase 1
Completed
- Conditions
- Staphylococcal Infections
- Interventions
- Biological: SA4Ag vaccine high doseBiological: PlaceboBiological: SA3Ag vaccineBiological: SA4Ag vaccine low doseBiological: SA4Ag vaccine mid doseProcedure: Blood drawProcedure: Blood sampleProcedure: Colonization swab sampleProcedure: Colonization swab samples
- Registration Number
- NCT01643941
- Lead Sponsor
- Pfizer
- Brief Summary
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus vaccine (SA3Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 65 to \<86 years. In addition, the study aims to assess the effect of the Staphylococcus aureus vaccine on the presence of the Staphylococcus aureus within the nose, throat and perineal skin of healthy adults aged 65 to \<86 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 284
Inclusion Criteria
- Healthy males and healthy postmenopausal females, aged 65 to <86 years at enrollment, as determined by medical history, physical examination, and the clinical judgment of the investigator to be eligible for the study. Subjects with preexisting chronic medical conditions determined to be stable may be included.
- Available for the entire duration of the study, and able to comply with scheduled visits, study plan, laboratory tests, and other study procedures including completion of the electronic diary (e diary) from Day 1 to Day 14 following vaccination.
- Able to be contacted by telephone during study participation.
- Male subjects who, in the opinion of the investigator, are biologically capable of fathering children, and who are sexually active with women of childbearing potential must agree to use a highly effective method of contraception throughout the study.
Exclusion Criteria
- Unstable chronic medical condition or disease requiring significant change in therapy or hospitalization for worsening disease within 3 months before receipt of study vaccine.
- Serious chronic medical disorders or any disorder that in the investigator's opinion precludes the subject from participating in the study.
- Donation of blood volume of 250 mL or greater or donation of plasma within 3 months prior to enrollment through conclusion of the study.
- Bleeding condition associated with prolonged bleeding time that may contraindicate intramuscular injection or blood draw including subjects taking anticoagulant, antiplatelet and/or antithrombotic agents except for low-dose daily aspirin within 30 days before enrollment through completion of Visit 6 (Day 29).
- Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine related components.
- Immunocompromised persons or subjects currently on immunosuppressive therapy or with a history of immunosuppressive therapy. History of immune-modifying drugs.
- Previous administration of S. aureus vaccination.
- Any infection proven or suspected to be caused by S. aureus within 6 months preceding study vaccination.
- Receipt of blood products or immunoglobulins (including monoclonal antibodies) within 12 months before enrollment through conclusion of the study.
- Participation in other investigational or interventional studies within 30 days before the current study begins and/or during study participation. Participation in purely observational studies is acceptable.
- Subjects who are investigational site staff members or subjects who are immediate family members (first-degree relatives) of investigational site staff members or Pfizer employees directly involved in the conduct of the trial.
- Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care. An ambulatory subject who is a resident of a retirement home or village is eligible for the trial.
- A Mini-Mental State Examination (MMSE) score of ≤21.
- For Phase 1 subjects only, any abnormality in screening hematology, coagulation, and/or blood chemistry laboratory values except as noted in protocol
- Subjects with known active disease with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV), or Phase 1 subjects with a positive screening test for HIV, HBV and/or HCV.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- Planned surgical procedure within 30 days following vaccination.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Colonization swab sample SA4Ag vaccine low dose 2 Colonization swab sample SA4Ag vaccine mid dose 4 Colonization swab sample SA3Ag vaccine 5 Colonization swab samples Placebo 3 SA4Ag vaccine high dose SA4Ag vaccine high dose 3 Blood draw SA4Ag vaccine high dose 2 Blood draw SA4Ag vaccine mid dose 5 Placebo Placebo 4 SA3Ag vaccine SA3Ag vaccine 5 Blood draw Placebo 1 SA4Ag vaccine low dose SA4Ag vaccine low dose 1 Blood draw SA4Ag vaccine low dose 2 SA4Ag vaccine mid dose SA4Ag vaccine mid dose 3 Colonization swab sample SA4Ag vaccine high dose 4 Blood sample SA3Ag vaccine
- Primary Outcome Measures
Name Time Method Number and proportion of subjects reporting solicited local reactions (size of redness and/or swelling and severity of pain at the injection site) and severity of the local reactions as self-reported on electronic diaries (e-diaries) 14 days Number and proportion of subjects reporting solicited systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain) and severity of solicited systemic events self-reported on electronic diaries 14 days Number and proportion of subjects reporting unsolicited AEs and serious adverse events (SAEs) categorized according to the Medical Dictionary for Regulatory Activities (MedDRA) 1 month (AEs); 6 months (SAEs) Number and proportion of Phase 1 subjects with abnormal hematology, coagulation and blood chemistry lab assessments 14 days Number and proportion of Phase 1 subjects with grading shifts in hematology, coagulation and blood chemistry laboratory assessments 14 days Proportion of subjects achieving antibody responses to specific vaccine components with results ≥ thresholds defined for each vaccine component based on immunoglobulin-binding and/or opsonphagocytic activity assays 1 month
- Secondary Outcome Measures
Name Time Method Immunoglobulin titers measured as geometric mean titers for each antigen at each applicable blood sampling time point, as measured by antigen-specific antibody levels using an immunoglobulin binding assay. various, up to 12 months Opsonophagocytic activity titers measured as geometric mean titers against S. aureus isolates at each applicable blood sampling time point. various, up to 12 months Immunoglobulin geometric mean fold rise for each of the vaccine components as measured by antigen-specific antibody levels using an immunoglobulin binding assay. 1 month Geometric mean fold rise on opsonophagocytic activity assay titers against S. aureus isolates. 1 month Proportion of subjects achieving antibody responses to specific antigens with results ≥ thresholds defined for each vaccine component at each applicable visit. Various, up to 12 months Proportion of subjects with ≥2-fold, ≥4-fold, ≥8-fold, ≥16-fold, and ≥32-fold increase in immunoglobulin titers from baseline to each applicable visit after vaccination for each antigen. Various, up to 12 months Proportion of subjects with ≥2-fold, ≥4-fold, ≥8-fold, ≥16-fold, and ≥32-fold increase in opsonophagocytic activity titers against S. aureus isolates from baseline to each applicable visit after vaccination. Various, up to 12 months
Trial Locations
- Locations (7)
Miami Research Associates
🇺🇸South Miami, Florida, United States
Broward Research Group
🇺🇸Hollywood, Florida, United States
PMG Research of Raleigh, LLC
🇺🇸Cary, North Carolina, United States
Benchmark Research
🇺🇸Austin, Texas, United States
Vince and Associates Clinical Research
🇺🇸Overland Park, Kansas, United States
Cincinnati Children's Hospital Medical Center Gamble Program for Clinical Studies
🇺🇸Cincinnati, Ohio, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States